| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ad20e68e485d7ccee74a75669ba5fb71 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-32 |
| filingDate |
2022-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_659ecd5ea4ee6eb0148164a346fdc8ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_847e8f900b4945bd6bc1be8e00f4eee8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dd38ed6e8879c493bed4ad4b037acce |
| publicationDate |
2022-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2022202495-A1 |
| titleOfInvention |
Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas |
| abstract |
Methods are provided for the treatment of relapsed and/or refractory solid tumors n(including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the nlike, using substituted heterocyclic derivative compounds and pharmaceutical compositions ncomprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1). |
| priorityDate |
2016-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |